Trial ID or NCT#



recruiting iconRECRUITING


This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.

Eligibility Criteria

Ages Eligible for Study: 4 Years to 11 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


R. Sharon Chinthrajah
R. Sharon Chinthrajah
Associate Professor of Medicine (Pulmonary and Critical Care Medicine)

Contact us to find out if this trial is right for you.


Sharon Chinthrajah, MD